NEW YORK, Feb. 18, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Tower Semiconductor Ltd. securities (NASDAQ:TSEM) from April 30, 2012 through January 13, 2016, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Tower Semiconductor investors under the federal securities laws.
To join the Tower Semiconductor class action, go to the firm’s website at http://www.rosenlegal.com/cases-816.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE
According to the lawsuit, throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) the value of net tangible assets of the acquisition of a fabrication facility from Micron Technology Inc. was artificially inflated; (2) the value of net tangible assets of the acquisition of 51% of TowerJazz Panasonic Semiconductor Co., Ltd. from Panasonic Corporation was artificially inflated; (3) Tower Semiconductor’s Series F Debentures were incorrectly accounted for to understate debt; and (4) as a result, Defendants’ statements about Tower Semiconductor’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. The lawsuit alleges that when the truth of these allegations entered the market through a research report issued by Spruce Point Capital Management, the value to Tower securities dropped, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-816.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 



